Literature DB >> 19224800

Trauma, systemic inflammatory response syndrome, dietary supplements, illicit steroid use and a questionable malignant hyperthermia reaction.

John F Capacchione1, Matthew C Radimer, Jeffrey S Sagel, Gregory P Kraus, Nyamkhishig Sambuughin, Sheila M Muldoon.   

Abstract

BACKGROUND: Malignant hyperthermia (MH) is a pharmacogenetic disorder of skeletal muscle calcium regulation associated primarily, but not exclusively, with mutations in the skeletal muscle ryanodine receptor. Associated environmental factors, however, may also be important for expression of the syndrome. METHODS AND
RESULTS: A 24-yr-old trauma patient developed a fulminant MH crisis after a 3 minute exposure to sevoflurane. A thorough evaluation of underlying co-morbidities revealed a number of environmental factors that could have altered skeletal muscle calcium regulation, and may have potentially influenced the effects of volatile inhaled anesthetics. Since MH is a syndrome characterized by abnormal skeletal muscle calcium regulation, other factors that alter calcium homeostasis may exacerbate the impact of inhaled MH-triggering drugs.
CONCLUSIONS: While a thorough history of MH episodes in a proband and family is emphasized as part of a complete preanesthetic evaluation, obtaining a history of other environmental entities that may alter calcium regulation may be equally important to knowing the family history.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19224800      PMCID: PMC2740653          DOI: 10.1213/ane.0b013e31819240a5

Source DB:  PubMed          Journal:  Anesth Analg        ISSN: 0003-2999            Impact factor:   5.108


  38 in total

Review 1.  Caffeine and excitation-contraction coupling in skeletal muscle: a stimulating story.

Authors:  A Herrmann-Frank; H C Lüttgau; D G Stephenson
Journal:  J Muscle Res Cell Motil       Date:  1999-02       Impact factor: 2.698

2.  A direct effect of testosterone on muscle cells in tissue culture.

Authors:  M L Powers; J R Florini
Journal:  Endocrinology       Date:  1975-10       Impact factor: 4.736

3.  Ca2+ uptake and Ca2+ release by skeletal muscle sarcoplasmic reticulum: differing sensitivity to inhalational anesthetics.

Authors:  T E Nelson; T Sweo
Journal:  Anesthesiology       Date:  1988-10       Impact factor: 7.892

Review 4.  Critical illness myopathy: what is happening?

Authors:  Oliver Friedrich
Journal:  Curr Opin Clin Nutr Metab Care       Date:  2006-07       Impact factor: 4.294

5.  Detection and determination of anabolic steroids in nutritional supplements.

Authors:  K J De Cock; F T Delbeke; P Van Eenoo; N Desmet; K Roels; P De Backer
Journal:  J Pharm Biomed Anal       Date:  2001-07       Impact factor: 3.935

6.  Increased intracellular Ca2+: a critical link in the pathophysiology of sepsis?

Authors:  S K Song; I E Karl; J J Ackerman; R S Hotchkiss
Journal:  Proc Natl Acad Sci U S A       Date:  1993-05-01       Impact factor: 11.205

7.  Testosterone stimulates intracellular calcium release and mitogen-activated protein kinases via a G protein-coupled receptor in skeletal muscle cells.

Authors:  Manuel Estrada; Alejandra Espinosa; Marioly Müller; Enrique Jaimovich
Journal:  Endocrinology       Date:  2003-08       Impact factor: 4.736

8.  Effects of chronic sepsis on contractile properties of fast twitch muscle in an experimental model of critical illness neuromyopathy in the rat.

Authors:  Benoit Rossignol; Gildas Gueret; Jean-Pierre Pennec; Julie Morel; Fabrice Rannou; Marie-Agnès Giroux-Metges; Hélène Talarmin; Maxime Gioux; Charles C Arvieux
Journal:  Crit Care Med       Date:  2008-06       Impact factor: 7.598

9.  Dantrolene sodium is able to reduce the resting ionic [Ca2+]i in muscle from humans with malignant hyperthermia.

Authors:  J R López; P Medina; L Alamo
Journal:  Muscle Nerve       Date:  1987-01       Impact factor: 3.217

10.  Halothane effects on human malignant hyperthermia skeletal muscle single calcium-release channels in planar lipid bilayers.

Authors:  T E Nelson
Journal:  Anesthesiology       Date:  1992-04       Impact factor: 7.892

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.